Next Article in Journal
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
Previous Article in Journal
Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer
Previous Article in Special Issue
Multifunctional Delivery Systems for Peptide Nucleic Acids
Open AccessArticle

Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2

Department of Epidemic Diseases Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(1), 39; https://doi.org/10.3390/ph14010039
Received: 22 November 2020 / Revised: 31 December 2020 / Accepted: 5 January 2021 / Published: 6 January 2021
Since its identification in Wuhan, China, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in 46 million cases and more than one million deaths worldwide, as of 30 October 2020. Limited data exist on the magnitude and durability of antibodies generated by natural infection with SARS-CoV-2 and whether they can provide long-lasting immunity from reinfection. Vaccination has proven the most effective measure for controlling and preventing pandemics and, thus, development of a vaccine against COVID-19 is a top priority. However, the doses required to induce effective, long-lasting antibody responses against SARS-CoV-2 remain undetermined. Here, we present the development of SARS-CoV-2 vaccine candidates encoding the viral spike (S) gene, generated using plasmid (p)DNA technology, and we demonstrate the eliciting of S-specific antibodies in mice after three and four doses. The magnitude of binding and neutralizing antibody responses with three doses of synthetic, codon-optimized, full-length S (S.opt.FL) vaccine is comparable to that generated after four doses, suggesting that three doses are sufficient to elicit robust immune responses. Conversely, four doses of S1.opt pDNA vaccine, containing the S globular head, are required to elicit high levels of neutralizing antibodies. Furthermore, the S.opt.FL pDNA vaccine induces the highest serum levels of interferon (IFN)-γ, a marker for activation of cellular immune responses. Overall, our data show that three doses of S.FL pDNA vaccine elicit potent neutralizing antibody responses, with preclinical data that support the immunogenicity of these COVID-19 vaccine candidates and provide justification for further translational studies. View Full-Text
Keywords: vaccine; SARS-CoV-2; virus; pDNA; immunity; antibody; COVID-19; coronavirus vaccine; SARS-CoV-2; virus; pDNA; immunity; antibody; COVID-19; coronavirus
Show Figures

Figure 1

MDPI and ACS Style

Almansour, I.; Macadato, N.C.; Alshammari, T. Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2. Pharmaceuticals 2021, 14, 39. https://doi.org/10.3390/ph14010039

AMA Style

Almansour I, Macadato NC, Alshammari T. Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2. Pharmaceuticals. 2021; 14(1):39. https://doi.org/10.3390/ph14010039

Chicago/Turabian Style

Almansour, Iman; Macadato, Nabela C.; Alshammari, Thamer. 2021. "Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2" Pharmaceuticals 14, no. 1: 39. https://doi.org/10.3390/ph14010039

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop